I can see us becoming standard of care quickly in several countries. Already there in ANZ but see UKI and Canada happening quickly too. That's 141 million population with just those, so ROW sales will have strong momentum behind it. Add in the other slower to build jurisdictions and India the great unknown at this stage. I think matriderm is a strong competitor in DACH regions but we should/have carved out a niche market there and will slowly convert other indications from there.
US building very nicely pre MTX and DW stated a month or two ago we're still missing from 20+ burn centres, so low hanging fruit ripe for the picking there too.
Synpath hopefully to add to the mix within the next 12 months. DW mentioned multiple times about beneficial acquisitions of podiatry related sales could boost sales momentum too - can see that happening at the right time.
Plenty going on to keep everyone on their toes!!!
I can see us becoming standard of care quickly in several...
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.09 |
Change
0.080(3.98%) |
Mkt cap ! $1.442B | |||
| Open | High | Low | Value | Volume |
| $2.03 | $2.09 | $2.03 | $1.476M | 710.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5010 | $2.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.09 | 135016 | 10 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.09 |
Change
0.080 ( 3.33 %) |
||||
| Open | High | Low | Volume | ||
| $2.03 | $2.09 | $2.03 | 302647 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| PNV (ASX) Chart |